Pricing Log in Create free account
Saturday 17 October 2026 Export MDXG’s income statement to Excel — free account

MiMedx Group, Inc

MDXG Healthcare Biotechnology

MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

4.43 0.25 −5.34%
Market cap
$682.2M
P/E
111×
Fwd P/E
−31.2×
Dividend yield
—
F-score
5/9
Altman Z
9.38
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.43
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership 22.66%

Capital & Financial Ratios $m

Market Cap 682.15
Revenue 355.17
Net Income 6.24
Free Cash Flow 44.43
Net Debt (118.63)
Current Ratio 5.33 (at or above 1.5: strong)
Debt/Equity 0.08 (at or below 0.5: strong)
P/E ratio 110.75 (above 35: high)
Fwd P/E (31.20) (negative: loss-making)
P/S ratio 1.84
P/B ratio 3.03
Past 5Y EPS Growth —
This Y EPS Growth (123.44%) (below 0%: weak)
Next Y EPS Growth 266.85% (at or above 15%: strong)
Next Y revenue growth (36.22%) (below 0%: weak)
Next 5Y EPS Growth (14.52%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 2.5×; over the ten years it ranged from 0.4× in 2018 to 6.5× in 2017.
P/E against its own 10 years 84.66%
10-year low 10-year high
P/S against its own 10 years 27.94%
10-year low 10-year high
P/B against its own 10 years 7.77%
10-year low 10-year high
EV/Sales against its own 10 years 21.05%
10-year low 10-year high
EV/FCF against its own 10 years 21.56%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 82 104 166 136
Receivables 54 56 76 41
Inventory 21 24 25 21
Other 2 8 10 7
164 192 277 205
2023 2024 2025 Q'26
Payables 9 7 15 8
ST’ Debt 1 1 2 2
Other 3 5 6 4
46 46 64 38

Compound Annual Growth %

10y 5y 3y
Sales 8.38% 11.02% 16.05%
Cash Flow 14.68% 0.00% 0.00%
Earnings 5.13% 0.00% 0.00%
Book Value 9.04% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 59 64 — — —
’25 88 99 114 118 419
’24 85 87 84 93 349
’23 72 81 82 87 321
’22 59 67 68 74 268
’21 60 68 63 51 242
’20 62 54 64 69 248
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 2 (10) — — —
’25 5 14 29 25 74
’24 6 22 20 19 66
’23 (4) 8 13 10 27
’22 (10) (3) 1 (6) (18)
’21 (7) 2 6 (3) (2)
’20 (12) (3) (5) (10) (30)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 (11) — — —
’25 5 14 29 25 73
’24 5 21 20 19 65
’23 (5) 7 12 10 25
’22 (10) (3) 1 (6) (19)
’21 (9) 1 6 (4) (5)
’20 (13) (4) (5) (13) (35)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.07) (0.10) — — —
’25 0.05 0.06 0.11 0.10 0.32
’24 0.06 0.12 0.05 0.05 0.28
’23 (0.06) 0.00 0.06 0.32 0.37
’22 (0.11) (0.11) (0.09) (0.02) (0.33)
’21 (0.09) (0.03) (0.04) 0.01 (0.15)
’20 (0.04) (0.08) (0.48) (0.17) (0.77)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 6.64 7.64 0.95 1.55 2.95 5.30 2.43 2.82 5.47 5.79

Analyst estimates 2026–2028

Powerpack
High 10.02 17.47 18.25 7.95 10.38 15.99 6.35 9.27 10.14 9.71
People
People Employees 690 — 753 696 735 811 867 895 837 808
Revenue/emp, $m 0.32 0.00 0.48 0.43 0.34 0.30 0.31 0.36 0.42 0.52
Income, $m
Income, $m Revenue 222 321 359 299 248 242 268 321 349 419
Gross margin, % 86.05 89.03 89.87 85.60 84.16 83.63 81.96 83.01 82.78 82.56
EBT 1 45 (3) (26) (62) (12) (20) 31 57 66
EBT margin, % 0.25 14.04 (0.95) (8.55) (24.79) (4.98) (7.37) 9.53 16.42 15.83
Net income 0 65 (30) (26) (49) (12) (20) 67 42 49
Depreciation 7 6 7 9 9 6 4 3 6 15
Per share, $
Per share, $ Revenue 2.09 3.03 3.40 2.80 2.29 2.19 2.37 2.76 2.37 2.83
Earnings 0.00 0.58 (0.28) (0.23) (0.77) (0.15) (0.33) 0.40 0.29 0.33
Cash flow 0.23 0.59 0.34 (0.37) (0.28) (0.02) (0.16) 0.23 0.45 0.50
Capex (0.07) (0.05) (0.09) (0.02) (0.04) (0.03) (0.01) (0.02) (0.01) (0.01)
Free cash flow 0.16 0.54 0.24 (0.39) (0.32) (0.05) (0.17) 0.21 0.44 0.49
Book value 1.26 0.70 0.47 0.32 0.00 0.00 (0.16) 1.23 1.31 1.74
Shares, m 106 106 106 107 108 110 113 116 147 148
Valuation, ×
Valuation, × P/E 3,650.00 21.28 0.00 0.00 0.00 0.00 0.00 19.68 34.36 20.52
P/S 4.19 4.29 0.53 2.71 3.96 2.75 1.25 2.85 4.05 2.39
P/B 6.98 18.67 3.81 23.57 0.00 8,128.44 0.00 6.42 7.32 3.90
EV/Sales 4.03 4.20 0.40 2.70 3.77 2.60 1.19 2.75 3.81 2.04
EV/FCF 53.18 23.46 5.58 (19.39) (26.88) (115.34) (16.46) 35.66 20.59 11.68
Cash, $m
Cash, $m Operating cash flow 24 63 36 (39) (30) (2) (18) 27 66 74
Capex (7) (5) (10) (2) (5) (3) (2) (2) (2) (1)
Free cash flow 17 58 26 (42) (35) (5) (19) 25 65 73
Balance, $m
Balance, $m Working capital 76 3 3 56 101 106 91 118 146 213
Total debt 0 0 0 66 49 49 50 49 19 18
Net debt (34) (27) (45) (3) (47) (38) (16) (33) (86) (148)
Shareholders’ equity 133 74 50 34 0 0 (18) 143 193 257
Returns, %
Returns, % ROA 0.24 41.16 (24.56) (17.64) (45.14) (8.42) (20.47) 28.37 16.87 16.02
ROIC 0.56 61.99 (51.46) (42.68) 0.00 0.00 0.00 21.12 34.22 36.84
ROE 0.32 62.60 (48.57) (60.87) (486.62) 48,297.06 410.78 93.37 25.26 21.61
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

MiMedx Group, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ANL Adlai Nortye Ltd. Sponsored ADR $710.1M — — — — +46.03% (above 0%: growing) — — Compare
OABI OmniAb, Inc. $687.7M — (loss-making) — (loss-making) +244.24% (above 0%: growing) n/m +211.16% (above 0%: growing) 95.45% (49.47%) Compare
ANNX Annexon, Inc. $682.5M — (loss-making) — — n/m −26.41% (below 0%: shrinking) 0.00% 0.00% Compare
MDXG MiMedx Group, Inc $682.2M 111× — (loss-making) −34.73% (below 0%: shrinking) n/m −174.83% (below 0%: shrinking) 68.96% (28.69%)
CADL Candel Therapeutics, Inc. $681.8M — (loss-making) — (loss-making) 0.00% n/m −93.35% (below 0%: shrinking) 0.00% 0.00% Compare
PHAR Pharming Group N.V. Sponsored ADR $681.6M 62.4× — (loss-making) −3.22% (below 0%: shrinking) −57.14% (below 0%: shrinking) −183.87% (below 0%: shrinking) 83.92% 1.44% Compare
GYRE Gyre Therapeutics, Inc. $678.6M — (loss-making) — (loss-making) −2.12% (below 0%: shrinking) n/m −130.45% (below 0%: shrinking) 92.41% (49.35%) Compare
AURA Aura Biosciences, Inc. $657.5M — (loss-making) — — n/m −56.26% (below 0%: shrinking) 0.00% 0.00% Compare
DSGN Design Therapeutics, Inc. $655.9M — (loss-making) — (loss-making) — n/m −7.00% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $681.7M — — −1.06% — −41.33% 0.00% 0.00%

All 614 Biotechnology stocks →

MiMedx Group, Inc (MDXG) key facts

  • Strength: MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.
  • MiMedx Group, Inc (MDXG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MDXG traded at $4.43, a market capitalization of $682.2 million.
  • Return on equity was 21.6% and debt-to-equity 0.08.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 9.38 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

MiMedx Group, Inc (MDXG) Latest News

14 Jul

Impact 5 ·
stockrow.com/MDXG · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com